Cellectar Biosciences (NASDAQ:CLRB) Coverage Initiated by Analysts at StockNews.com

by · The Markets Daily

Stock analysts at StockNews.com started coverage on shares of Cellectar Biosciences (NASDAQ:CLRB – Get Free Report) in a note issued to investors on Friday. The brokerage set a “sell” rating on the biopharmaceutical company’s stock.

A number of other equities research analysts also recently issued reports on the stock. LADENBURG THALM/SH SH began coverage on shares of Cellectar Biosciences in a research report on Thursday, December 5th. They issued a “buy” rating and a $13.00 price objective for the company. Oppenheimer reiterated a “market perform” rating on shares of Cellectar Biosciences in a report on Wednesday, December 11th.

Read Our Latest Analysis on Cellectar Biosciences

Cellectar Biosciences Stock Down 1.3 %

Shares of NASDAQ:CLRB opened at $0.24 on Friday. The business’s 50 day moving average is $1.59 and its 200 day moving average is $2.08. Cellectar Biosciences has a 12-month low of $0.22 and a 12-month high of $4.45. The stock has a market cap of $9.70 million, a price-to-earnings ratio of -0.14 and a beta of 0.89.

Cellectar Biosciences (NASDAQ:CLRB – Get Free Report) last posted its earnings results on Tuesday, October 29th. The biopharmaceutical company reported ($0.51) earnings per share (EPS) for the quarter. As a group, equities research analysts expect that Cellectar Biosciences will post -1.59 earnings per share for the current year.

Institutional Trading of Cellectar Biosciences

Hedge funds have recently added to or reduced their stakes in the stock. Rosalind Advisors Inc. increased its stake in shares of Cellectar Biosciences by 35.7% during the 3rd quarter. Rosalind Advisors Inc. now owns 3,671,550 shares of the biopharmaceutical company’s stock worth $7,857,000 after purchasing an additional 965,934 shares during the last quarter. AIGH Capital Management LLC lifted its stake in Cellectar Biosciences by 8.2% in the second quarter. AIGH Capital Management LLC now owns 3,036,187 shares of the biopharmaceutical company’s stock valued at $7,590,000 after purchasing an additional 231,270 shares during the last quarter. XTX Topco Ltd grew its holdings in Cellectar Biosciences by 432.4% during the second quarter. XTX Topco Ltd now owns 63,304 shares of the biopharmaceutical company’s stock valued at $158,000 after purchasing an additional 51,413 shares during the period. Sequoia Financial Advisors LLC purchased a new stake in Cellectar Biosciences in the third quarter worth $51,000. Finally, Oppenheimer & Co. Inc. purchased a new position in shares of Cellectar Biosciences during the 3rd quarter valued at $27,000. Institutional investors own 16.41% of the company’s stock.

Cellectar Biosciences Company Profile

(Get Free Report)

Cellectar Biosciences, Inc, a clinical biopharmaceutical company, focuses on the discovery, development, and commercialization of drugs for the treatment of cancer. Its lead phospholipid drug conjugate (PDC) candidate is CLR 131 (iopofosine I-131), which is in Phase 2 clinical study for patients with B-cell malignancies; Phase 2a clinical study for patients with relapsed or refractory (r/r) Waldenstrom's macroglobulinemia cohort, r/r multiple myeloma (MM) cohort, and r/r non-Hodgkin's lymphoma cohort; Phase 1 clinical study for r/r pediatric patients with select solid tumors, lymphomas, and malignant brain tumors; and Phase 1 clinical study for r/r head and neck cancer.

Read More